# GLAUKOS Corp: financial statements, quarterly GKOS · NYSE · CIK 1192448 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/gkos.md) · [Financials](/companies/gkos/financials.md) · [Filings](/companies/gkos/filings.md) · [Insiders](/companies/gkos/insiders.md) Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/gkos/financials.md?period=annual). ## Income statement | Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [82.4 d](/filings/0001193125-26-061944.md) | [85.6](/filings/0001558370-25-006041.md) | [95.7](/filings/0001558370-25-010113.md) | [96.7](/filings/0001104659-25-104529.md) | [105 d](/filings/0001193125-26-061944.md) | [107](/filings/0001193125-26-193004.md) | [124](/filings/0001193125-26-324201.md) | [134](/filings/0001193125-26-436400.md) | [143 d](/filings/0001193125-26-061944.md) | [151](/filings/0001193125-26-193004.md) | [186](/filings/0001193125-26-324201.md) | [211](/filings/0001193125-26-436400.md) | | Cost of revenue | $m | [18.9 d](/filings/0001193125-26-061944.md) | [20.3](/filings/0001558370-25-006041.md) | [22.6](/filings/0001558370-25-010113.md) | [22.6](/filings/0001104659-25-104529.md) | [28.6 d](/filings/0001193125-26-061944.md) | [24.3](/filings/0001193125-26-193004.md) | [26.9](/filings/0001193125-26-324201.md) | [28.8](/filings/0001193125-26-436400.md) | [31.8 d](/filings/0001193125-26-061944.md) | [33.3](/filings/0001193125-26-193004.md) | [34.0](/filings/0001193125-26-324201.md) | [31.2](/filings/0001193125-26-436400.md) | | Gross profit | $m | [63.5 d](/filings/0001193125-26-061944.md) | [65.4](/filings/0001558370-25-006041.md) | [73.1](/filings/0001558370-25-010113.md) | [74.1](/filings/0001104659-25-104529.md) | [76.9 d](/filings/0001193125-26-061944.md) | [82.3](/filings/0001193125-26-193004.md) | [97.2](/filings/0001193125-26-324201.md) | [105](/filings/0001193125-26-436400.md) | [(1.5) d](/filings/0001193125-26-061944.md) | [117](/filings/0001193125-26-193004.md) | [152](/filings/0001193125-26-324201.md) | [180](/filings/0001193125-26-436400.md) | | Research and development | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [26.9](/filings/0001193125-26-436400.md) | not reported | not reported | not reported | [31.0](/filings/0001193125-26-436400.md) | | Selling, general and administrative | $m | [63.0 d](/filings/0001193125-26-061944.md) | [62.0](/filings/0001558370-25-006041.md) | [66.2](/filings/0001558370-25-010113.md) | [64.0](/filings/0001104659-25-104529.md) | [69.0 d](/filings/0001193125-26-061944.md) | [70.7](/filings/0001193125-26-193004.md) | [83.4](/filings/0001193125-26-324201.md) | [83.0](/filings/0001193125-26-436400.md) | [94.7 d](/filings/0001193125-26-061944.md) | [92.9](/filings/0001193125-26-193004.md) | [116](/filings/0001193125-26-324201.md) | [131](/filings/0001193125-26-436400.md) | | Operating income | $m | [(38.6) d](/filings/0001193125-26-061944.md) | [(39.1)](/filings/0001558370-25-006041.md) | [(30.0)](/filings/0001558370-25-010113.md) | [(24.7)](/filings/0001104659-25-104529.md) | [(28.7) d](/filings/0001193125-26-061944.md) | [(20.7)](/filings/0001193125-26-193004.md) | [(22.7)](/filings/0001193125-26-324201.md) | [(16.4)](/filings/0001193125-26-436400.md) | [(140) d](/filings/0001193125-26-061944.md) | [(19.9)](/filings/0001193125-26-193004.md) | [(17.3)](/filings/0001193125-26-324201.md) | [0.8](/filings/0001193125-26-436400.md) | | Interest expense | $m | [3.4 d](/filings/0001558370-24-001630.md) | [3.5](/filings/0001558370-24-006573.md) | [3.4](/filings/0001558370-25-010113.md) | [1.7](/filings/0001104659-25-104529.md) | [1.6 d](/filings/0001193125-26-061944.md) | [1.2](/filings/0001193125-26-193004.md) | [1.2](/filings/0001193125-26-324201.md) | [1.2](/filings/0001193125-26-436400.md) | [1.1 d](/filings/0001193125-26-061944.md) | [1.1](/filings/0001193125-26-193004.md) | [1.5](/filings/0001193125-26-324201.md) | [1.1](/filings/0001193125-26-436400.md) | | Income tax | $m | [0.1 d](/filings/0001193125-26-061944.md) | [0.4](/filings/0001558370-25-006041.md) | [0.3](/filings/0001558370-25-010113.md) | [0.2](/filings/0001104659-25-104529.md) | [(0.1) d](/filings/0001193125-26-061944.md) | [0.3](/filings/0001193125-26-193004.md) | [0.2](/filings/0001193125-26-324201.md) | [0.2](/filings/0001193125-26-436400.md) | [(6.2) d](/filings/0001193125-26-061944.md) | [0.5](/filings/0001193125-26-193004.md) | [0.7](/filings/0001193125-26-324201.md) | [0.3](/filings/0001193125-26-436400.md) | | Net income | $m | [(36.8) d](/filings/0001193125-26-061944.md) | [(40.8)](/filings/0001558370-25-006041.md) | [(50.5)](/filings/0001558370-25-010113.md) | [(21.4)](/filings/0001104659-25-104529.md) | [(33.6) d](/filings/0001193125-26-061944.md) | [(18.1)](/filings/0001193125-26-193004.md) | [(19.7)](/filings/0001193125-26-324201.md) | [(16.2)](/filings/0001193125-26-436400.md) | [(134) d](/filings/0001193125-26-061944.md) | [(19.8)](/filings/0001193125-26-193004.md) | [(18.4)](/filings/0001193125-26-324201.md) | [2.0](/filings/0001193125-26-436400.md) | | Diluted EPS | $ per share | not reported | [(0.82)](/filings/0001558370-25-006041.md) | [(1.00)](/filings/0001558370-25-010113.md) | [(0.39)](/filings/0001104659-25-104529.md) | not reported | [(0.32)](/filings/0001193125-26-193004.md) | [(0.34)](/filings/0001193125-26-324201.md) | [(0.28)](/filings/0001193125-26-436400.md) | not reported | [(0.34)](/filings/0001193125-26-193004.md) | [(0.31)](/filings/0001193125-26-324201.md) | [0.03](/filings/0001193125-26-436400.md) | | Basic EPS | $ per share | not reported | [(0.82)](/filings/0001558370-25-006041.md) | [(1.00)](/filings/0001558370-25-010113.md) | [(0.39)](/filings/0001104659-25-104529.md) | not reported | [(0.32)](/filings/0001193125-26-193004.md) | [(0.34)](/filings/0001193125-26-324201.md) | [(0.28)](/filings/0001193125-26-436400.md) | not reported | [(0.34)](/filings/0001193125-26-193004.md) | [(0.31)](/filings/0001193125-26-324201.md) | [0.03](/filings/0001193125-26-436400.md) | - Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax - Cost of revenue: us-gaap:CostOfGoodsAndServicesSold - Gross profit: us-gaap:GrossProfit - Research and development: us-gaap:ResearchAndDevelopmentExpense - Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense - Operating income: us-gaap:OperatingIncomeLoss - Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating - Income tax: us-gaap:IncomeTaxExpenseBenefit - Net income: us-gaap:NetIncomeLoss - Diluted EPS: us-gaap:EarningsPerShareDiluted - Basic EPS: us-gaap:EarningsPerShareBasic ## Balance sheet | Line item | Unit | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Cash and equivalents | $m | [93.5](/filings/0001193125-26-061944.md) | [42.5](/filings/0001558370-24-006573.md) | [68.1](/filings/0001558370-24-010729.md) | [100](/filings/0001558370-24-014295.md) | [170](/filings/0001193125-26-061944.md) | [114](/filings/0001558370-25-006041.md) | [101](/filings/0001558370-25-010113.md) | [98.2](/filings/0001104659-25-104529.md) | [90.8](/filings/0001193125-26-436400.md) | [104](/filings/0001193125-26-193004.md) | [114](/filings/0001193125-26-324201.md) | [162](/filings/0001193125-26-436400.md) | | Current assets | $m | [395](/filings/0001558370-25-001402.md) | [389](/filings/0001558370-24-006573.md) | [384](/filings/0001558370-24-010729.md) | [397](/filings/0001558370-24-014295.md) | [450](/filings/0001193125-26-061944.md) | [445](/filings/0001558370-25-006041.md) | [436](/filings/0001558370-25-010113.md) | [455](/filings/0001104659-25-104529.md) | [475](/filings/0001193125-26-436400.md) | [486](/filings/0001193125-26-193004.md) | [516](/filings/0001193125-26-324201.md) | [580](/filings/0001193125-26-436400.md) | | Total assets | $m | [940](/filings/0001558370-25-001402.md) | [933](/filings/0001558370-24-006573.md) | [920](/filings/0001558370-24-010729.md) | [927](/filings/0001558370-24-014295.md) | [975](/filings/0001193125-26-061944.md) | [966](/filings/0001558370-25-006041.md) | [987](/filings/0001558370-25-010113.md) | [999](/filings/0001104659-25-104529.md) | [893](/filings/0001193125-26-436400.md) | [893](/filings/0001193125-26-193004.md) | [921](/filings/0001193125-26-324201.md) | [980](/filings/0001193125-26-436400.md) | | Current liabilities | $m | [74.0](/filings/0001558370-25-001402.md) | [72.2](/filings/0001558370-24-006573.md) | [70.1](/filings/0001558370-24-010729.md) | [71.7](/filings/0001558370-24-014295.md) | [75.1](/filings/0001193125-26-061944.md) | [68.5](/filings/0001558370-25-006041.md) | [79.1](/filings/0001558370-25-010113.md) | [87.5](/filings/0001104659-25-104529.md) | [101](/filings/0001193125-26-436400.md) | [89.4](/filings/0001193125-26-193004.md) | [102](/filings/0001193125-26-324201.md) | [127](/filings/0001193125-26-436400.md) | | Total liabilities | $m | [479](/filings/0001558370-25-001402.md) | [483](/filings/0001558370-24-006573.md) | [255](/filings/0001558370-24-010729.md) | [258](/filings/0001558370-24-014295.md) | [208](/filings/0001193125-26-061944.md) | [202](/filings/0001558370-25-006041.md) | [222](/filings/0001558370-25-010113.md) | [230](/filings/0001104659-25-104529.md) | [237](/filings/0001193125-26-436400.md) | [222](/filings/0001193125-26-193004.md) | [238](/filings/0001193125-26-324201.md) | [262](/filings/0001193125-26-436400.md) | | Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Shareholders' equity | $m | [462](/filings/0001558370-25-001402.md) | [451](/filings/0001558370-24-006573.md) | [665](/filings/0001558370-24-010729.md) | [669](/filings/0001558370-24-014295.md) | [767](/filings/0001193125-26-061944.md) | [764](/filings/0001558370-25-006041.md) | [765](/filings/0001558370-25-010113.md) | [770](/filings/0001104659-25-104529.md) | [656](/filings/0001193125-26-436400.md) | [671](/filings/0001193125-26-193004.md) | [682](/filings/0001193125-26-324201.md) | [717](/filings/0001193125-26-436400.md) | - Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue - Current assets: us-gaap:AssetsCurrent - Total assets: us-gaap:Assets - Current liabilities: us-gaap:LiabilitiesCurrent - Total liabilities: us-gaap:Liabilities - Long-term debt: not reported - Current portion of debt: not reported - Shareholders' equity: us-gaap:StockholdersEquity ## Cash flow | Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Operating cash flow | $m | [(10.7) d](/filings/0001193125-26-061944.md) | [(33.9)](/filings/0001558370-25-006041.md) | [(18.4) d](/filings/0001558370-25-010113.md) | [(9.6) d](/filings/0001104659-25-104529.md) | [0.5 d](/filings/0001193125-26-061944.md) | [(18.5)](/filings/0001193125-26-193004.md) | [7.0 d](/filings/0001193125-26-324201.md) | [(10.1) d](/filings/0001193125-26-436400.md) | [6.8 d](/filings/0001193125-26-061944.md) | [(12.5)](/filings/0001193125-26-193004.md) | [14.8 d](/filings/0001193125-26-324201.md) | [38.6 d](/filings/0001193125-26-436400.md) | | Capital expenditure | $m | [4.2 d](/filings/0001193125-26-061944.md) | [1.0](/filings/0001558370-25-006041.md) | [2.1 d](/filings/0001558370-25-010113.md) | [1.5 d](/filings/0001104659-25-104529.md) | [1.7 d](/filings/0001193125-26-061944.md) | [1.9](/filings/0001193125-26-193004.md) | [1.2 d](/filings/0001193125-26-324201.md) | [1.6 d](/filings/0001193125-26-436400.md) | [2.9 d](/filings/0001193125-26-061944.md) | [4.0](/filings/0001193125-26-193004.md) | [2.7 d](/filings/0001193125-26-324201.md) | [2.1 d](/filings/0001193125-26-436400.md) | - Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities - Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment ## Shares | Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Diluted shares (weighted) | millions of shares | [47.9](/filings/0001558370-24-006573.md) | [48.3](/filings/0001558370-24-010729.md) | [48.7](/filings/0001558370-24-014295.md) | [49.6](/filings/0001558370-25-006041.md) | [50.7](/filings/0001558370-25-010113.md) | [55.0](/filings/0001104659-25-104529.md) | [56.6](/filings/0001193125-26-193004.md) | [57.2](/filings/0001193125-26-324201.md) | [57.4](/filings/0001193125-26-436400.md) | [58.0](/filings/0001193125-26-193004.md) | [58.8](/filings/0001193125-26-324201.md) | [61.2](/filings/0001193125-26-436400.md) | - Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding Shares outstanding: 59,196,870 at 2026-10-26, from the cover of the [10-Q filed 2026-10-28](/filings/0001193125-26-436400.md) (dei:EntityCommonStockSharesOutstanding). Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 29, 2026, 05:20 ET. No prices; not investment advice.